Nephron Research Joins Forces with Santander for Healthcare Equity Research Expansion

Nephron Research Partners with Santander for U.S. Equity Research

In a significant development for the healthcare investment landscape, Nephron Research LLC, a prominent independent equity research firm, has announced a strategic alliance with Santander Corporate Investment Banking, specifically their U.S. entity known as Santander U.S. Capital Markets LLC. This partnership aims to bolster the research offerings available to clients in the healthcare sector across the United States.

Founded in 2017 by Joshua Raskin and Eric Percher, Nephron Research is widely recognized for its in-depth analysis and forward-thinking strategies in healthcare equity research. The firm's expertise is set to amplify Santander's service capabilities, providing a wealth of knowledge and insights to institutional clients. This collaboration will benefit Santander by incorporating Nephron's established research and solid relationships within the healthcare industry, enhancing the bank’s existing portfolio.

The Strategic Benefits of the Alliance

The partnership is designed to utilize the strengths of both organizations. By aligning with Santander, known for its vast geographical reach and profound understanding of financial markets, Nephron Research anticipates a significant expansion of its operational footprint. The synergy created by this alliance will allow both firms to better serve their clients, tapping into new growth opportunities that were previously unavailable.

Joshua Raskin and Eric Percher expressed their excitement about joining forces with a major global bank. They noted how this partnership not only validates Nephron's existing market position but also opens up new avenues for mutual growth in the competitive healthcare investment space. “We look forward to leveraging our market-leading healthcare research platform with Santander's global scale and financial markets expertise,” Raskin stated, emphasizing the potential for enhanced client service.

David Hermer, Head of Santander CIB U.S., echoed these sentiments, highlighting the importance of such alliances in solidifying Santander's growth strategy within the U.S. market. He stated, “By partnering with leading research firms across key sectors, we are expanding the insights and capabilities we bring to clients.” This forward-thinking approach will undoubtedly enhance the value delivered to their corporate and institutional client base, reinforcing Santander's commitment to evolving as a trusted financial partner.

Nephron’s Independent Status

Under the terms of their agreement, Nephron Research will retain its independence as an equity research provider, enabling it to maintain its focus on client value creation without interference. This independence is critical to its identity, ensuring that its research remains unbiased and objective, crucial attributes for institutional investors navigating the complexities of healthcare investments.

Nephron Research has carved out a substantial niche within the healthcare sector, analyzing 84 companies and providing pivotal insights into their performance and market trends. The firm’s wealth of experience and sharp analytical lens offers clients a unique perspective that is vital for making informed investment decisions.

About Santander

Banco Santander, headquartered in Spain and founded in 1857, is recognized as one of the largest banks globally by market capitalization. The bank operates across five core businesses: Retail and Commercial Banking, Digital Consumer Banking, Corporate Investment Banking, Wealth Management, and Payments. This operating model enables Santander to leverage global scale while ensuring local relevance, catering to various client needs—from individuals to governmental organizations.

Santander CIB focuses on providing tailored services that cater specifically to the demands of corporate and institutional clients, evidencing its readiness to embrace collaboration with specialized firms like Nephron Research. This commitment reflects Santander's mission to support sustainable growth through responsible banking practices.

By teaming up with Nephron Research, Santander is not only reinforcing its service offerings in the U.S. capital markets but also committing to uphold their goal to aid prosperity in a simple, personal, and fair manner.

This partnership represents a promising development for both organizations and underscores how strategic alliances can drive progress in the financial and healthcare sectors.